Sys Rev Pharm 2021; 12(5): 301-303
A multifaceted review journal in the field of pharmacy
E-ISSN 0976-2779 P-ISSN 0975-8453

Research Article

Large Altitude Exposed Bovine Aspirin Treatment Blood Coagulation and Pulmonary Hypertension

Iqra Zamir1, Sana2, Syed Usman Ummer3*

[1]Department of Medical Sciences, Basic Health Unit Saroopwala, Hafizabad, Pakistan
[2]Department of Medical Sciences, King Edward medical University, Lahore, Pakistan
[3]Department of Medical Sciences, DHQ Hospital, Sheikhupura, Pakistan

Article History: *Submitted: 03.06.2021* *Accepted: 17.06.2021* *Published: 24.06.2021*

ABSTRACT

Aim: Eered to cross a recreated 4,700 m high at an altitude of 450 meters. The following changes have resulted: pulsate increases (35 b/min), average vessel pressure (8 tort), red cell counts (25%), hemoglobin (34%), hematocrit (34%), blood pH (0.037 units), white blood cell counts (22%), blood thickener (19%) and prothrombin time (9 percent). There were decreases in the number of thrombocytes (8%) and the removal of club (23 percent). Our current research was conducted at Mayo Hospital, Lahore from March 2019 to February 2020. This high reaction was not affected by corrosive acetylsalicylic acid (ibuprofen) orally regulated over 14 days (90 mg/day). The findings provide more evidence of prostaglandin as a lung hypertension arbitrator.

***Correspondence:**
Syed Usman Ummer, Department of Medical Sciences, DHQ Hospital, Sheikhupura, Pakistan, E-mail: phdali786@gmail.com

INTRODUCTION

It has been recommended that in cases of dietary hypoxia, aspiratory vasoconstriction be identified with the mixing and arrival of prostaglandins from lung tissue that may be impeded by mixing intravenous ibuprofen (Anderson FL, *et al.*, 1972; Genton E, *et al.*, 1970; Goodman LS and Gilman A, 1970). In cows, prostaglandin F2 ¢ x is orchestrated in the Tung bounty and rises pressure in the aspiratory artery. Opening at high altitude can also cause changes in blood coagulation (Nour-Eldin F, 1967). Current examination has been attempted to investigate in hypoxic cows (1) the pressure factor of aspirated blood vessels and some components associated with blood coagulation as well, (2) the conceivable impact of orally controlled ibuprofen on these variables (Piper PJ and Vane JR, 1969). In 1998, during the Second World Symposium on Pulmonary Hypertension (PH) held in Evian, France, a clinical classification of PH was proposed. The aim of the Evian classification was to individualize different categories sharing similarities in pathophysiological mechanisms, clinical presentation, and therapeutic options. The Evian classification is now well accepted and widely used in clinical practice, especially in specialized centers. In addition, this classification has been used by the U.S. Food and Drug Administration and the European Agency for Drug Evaluation for the labeling of newly approved medications in PH. In 2003, during the Third World Symposium on Pulmonary Arterial Hypertension held in Venice, Italy, it was decided to maintain the general architecture and philosophy of the Evian classification. However, some modifications have been proposed, mainly to abandon the term “primary pulmonary hypertension” and to replace it with “idiopathic pulmonary hypertension”; to reclassify pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis; to update risk factors and associated conditions for pulmonary arterial hypertension and to propose guidelines in order to improve the classification of congenital systemic-to-pulmonary shunts (Nour-Eldin F, 1967). Pulmonary hypertension primary pulmonary hypertension; or secondary pulmonary hypertension according to the presence of identified causes or risk factors. Since the second World Symposium on pulmonary hypertension held in Evian, in 1998, a clinical classification was established in order to individualize different categories of PH sharing similar pathological findings, similar hemodynamic characteristics and, similar management. pulmonary hypertension due to chronic lung disease and/or hypoxia; chronic thromboembolic pulmonary hypertension (Group 4); and pulmonary hypertension due to unclear multifactorial mechanisms. During the successive world meetings, a series of changes were carried out, reflecting some progresses in the understanding of the disease. However, the general architecture and the philosophy of the clinical classification were unchanged. The current clinical classification of pulmonary hypertension is now well accepted and, widely used in the daily practice of pulmonary hypertension experts. It has been adopted by the Guidelines Committee of the Societies of Cardiology and, Pneumology. Moreover, this classification is currently used by the U.S. Food and Drug Administration and the European Agency for Drug Evaluation for the labelling of new drugs approved for pulmonary hypertension (Piper PJ and Vane JR, 1969).

METHODOLOGY

Six emasculated bull calves (3 Brown Swiss and 3 Simmental), 8 to 9 long, fairly old, weighing approximately 220 kg, were used. The calves were cared for according to a total and adjusted distribution of pellets and 1 kg of roughage per day. Feeding was accessible, not compulsory, between 9 a.m. and 6 p.m. and water was available at all times. Our current research was conducted at Mayo Hospital, Lahore from March 2019 to February 2020. The six calves were divided into two even groups according to breed and weight, and then arbitrarily divided between an "ibuprofen" (corrosive acetylsalicylic acid) group and a "control" group. The creatures in the headache medication group received a total of about 90 mg of ibuprofen per kg of body weight per day. The anti-inflammatory drug was presented orally as an aqueous suspension with a plastic cylinder connected to a 3-piece plastic needle (06:00, 14:00 and 22:00 hrs). The test was performed under neutral thermos conditions (18°C, half RH) in a suitable chamber with a low pressure factor. After a control time of 7 days at an altitude of 400 m, the creatures were discovered for 14 days at a height of 4,500 m. The ascent was carried out in 48 hours in 7 steps of equivalent height. Blood tests were performed approximately 10 minutes after the catheterization, from the jugular vein to the needles through the catheter,

after each estimate of circulatory tension. The hr.1 test (30 ml, heparinized) was used for the assurance of Red (RBC) and White (WBC) numbers (Coulter counter, D1), (Hb-cyanide), Hematocrit (HCT) (Clay Adams microcentrifuge) and explicit blood gravity (CuSO4 technique). Red blood cell recordings determined Mean Corpuscular Volume (MCV), Mean Corpuscular Hemoglobin (MCH) and Mean Corpuscular Hemoglobin Binding (MCHC). Test no. 2 (2 ml, heparinized, anaerobic) was used for a reliable estimate of blood pH; the readings were corrected for Tre. The hr. test was used to determine the limits of blood thickening. Thrombocyte count, clump, blood and plasma clotting season, and prothrombin time ("Quick") were resolved by the techniques described by Nour-Eldin.

RESULTS

Oral administration of an anti-inflammatory drug (90 mg/kg, day) in 3 equivalent parts) to 2 calves for 2 days resulted in free ibuprofen groups in the blood of 0.8; in addition, 1.7 tissues/100 ml of blood separately in blood tests carried out 2 hours after the last part was administered. A correlation between the 2 samples showed that, in the treatment of headache, the withdrawal of the clustered treated creatures was more modest (49.4 *vs* 53.6 go, P<0.06) and leukocythemia was less (8,815 *vs* 12,177/mm3, P<0.002). This last distinction is probably due to the very strong motivation in only one of the control creatures. There was no evidence of drug treatment of headaches on the PAP. Apart from these distinctions, the creatures in both groups reacted in the same way to the height. The results are consistent with this and are presented as the midpoints of each of the 6 calves *(Table 1)*. The PAP adjustments are shown. Exposure at 4500 m caused corresponding changes: increases were recorded for FC, PAP, RBC, Hb, HCT, MCV and MCH, explicit blood severity, blood pH, WBC, blood clotting time and prothrombin time (Prothrombin Time (PT); decreases were seen for thrombocyte count, agglutinant removal and a trace of a decrease in MCHC.

Table 1: The midpoints of each of the 6 calves

Drug	Mechanism	Metabolism	Dose for therapeutic	Dose for DVT prophylaxis	Therapeutic target	Reversal agent
Heparin	Potentiates anti-thromibin: lia, Xa, xila inhibition	Hepatic reticulo-endothelial system and 50% renal excretion	Bolus=80 U kg^{-1} Infusion=18 U kg^{-1} h^{-1}: adjust to target PTT	5000 u SC twice to thrice daily	APTT=60-80 seconds	Protamine start with 25-50 mg
LMWH	Potentiates anti-thromibin: Xa inhibition	Mainly renal excretion	1 mg kg^{-1} SC twice daily	40mg SC once daily	Chromogenic anti-Xa assay: 0.3 1.0 anti-Xa U mL^{-1}	None
Danaparoid	Potentiates antithormbin: Xa inhibition and lia to a lesser extent	Renal	750-1250 units three times daily	750 units twice daily	Chromogenic anti-Xa assay: 0.5 0.8 anti-Xa U mL^{-1}	None
Fondaparinux	Potentiates antithormbin: Xa inhibition	Renal	5, 7.5, or 10 mg SC once daily	2.5 mg SC once daily	Chromogenic anti-Xa assay	None
Rivaroxiban	Direct Xa inhibition	Likely liver		10mg PO once daily	Chromogenic anti-Xa assay	None
Warfarin	Prevents carboxylation of X, IX, VII, II, protein C and S	Hepatic, marked genetic variability	2-10 mg PO daily, adjust to target INR	-	INR=2 to 4	Vitamin K: 10-0 mg PO or plasma: start with 2-4 units
Bavalirudin	Direct thrombin Inhibition	Proteolytic cleavage and renal (20%)	Bolus=1 mg kg^{-1}	-	aPTT=60 to 80 seconds	None
			Infusion=0.2 mg kg^{-1}			
			h-1: adjust to target PTT			
Desirudin	Direct thrombin Inhibition	Renal	-	10 15 mg twice daily	Prolongs the aPTT	None
Argatroban	Direct thrombin Inhibition	Hepatic	Infusion=2 μg kg^{-1} min^{-1}: adjust to target PTT	-	aPTT=60-80 seconds: may prolong INR	None
Dabigetran (etexilate)	Direct thrombin Inhibition	Renal (unchanged) and some conjugation with glucuronic acid	150 mg PO twice daily	150 mg PO once daily	Fixed dose: no laboratory monitoring required	None

DISCUSSION

As for the impact of anti-inflammatory drugs on the limits of blood clotting, there was just one sign of decreased coagulation withdrawal, but in all cases, the application of headache medication had no effect (Reeves JT, *et al.*, 1972). Comparative measurements of oral ibuprofen in humans would result in blood fixations approximately several times higher than those observed in the current examination (Rosenthal TB, 1948). This distinction is probably due to contrasts in the pH of the stomach. The tureen pH (5 to 7) thought to be present with the lower pH of the human stomach would generally decrease dissemination in the blood; a moderately high pH favors a more ionized type of headache medication that has less dispersion than the un-ionized structure (Samuelsson B, 1964). Said and colleagues recommended that pulmonary hypertension caused by hypoxia in the diet be reduced by an intravenous mixture of anti-inflammatory drugs (approximately 45 mg ~ 100 ml of free ibuprofen in the blood) (Said SI, *et al.*, 1974). Contrary to this conclusion, no transient inhibitory effect was observed in aspirated hypertension triggered by hypoxia in calves injected with ibuprofen (approx. 0.6 tissue/100 ml headache medication in blood) or in rodents (10 tissue/100 ml headache medication in water) (Singh I and Chohan IS, 1974).

CONCLUSION

Limiting the mixture of prostaglandin in the lung of a guinea pig needs just 0.2 to 0.6 mg of free headaches per 100 ml, values close to the present test. Our findings indicate, however, that extended ibuprofen therapy does not interfere with pneumonia. You also affirm that prostaglandins do not affect vasoconstriction caused by hypoxia.

REFERENCES

1. Anderson FL, Kralios AC, Tsagaris TJ, Kuida H. Effects of prostaglandins F2α and E2 on the bovine circulation. Proc Soc exp Biol. 1972; 140(3): 1049-1053.
2. Genton E, Ross AM, Takeda YA, Vogel JH. Alterations in Blood Coagulation at High Altitude. Hypoxia, High Altitude and the Heart. 1970; 5: 32-40.
3. Goodman LS, Gilman A. The Pharmacological Basis of Therapeutics. The MacMillan Company. 1970.
4. Nour-Eldin F. Blood Coagulation Simplified. Butterworth. 1967.
5. Piper PJ, Vane JR. Release of additional factors in anaphylaxis and its antagonism by anti-inflammatory drugs. Nature. 1969; 223(5201): 29-35.
6. Reeves JT, Daoud FS, Estridge MI. Pulmonary hypertension caused by minute amounts of endotoxin in calves. J appl Physiol. 1972; 33(6): 739-743.
7. Rosenthal TB. The effect of temperature on the pH of blood and plasma in vitro. J biol Chem. 1948;173(1):25-30.
8. Samuelsson B. Identification of Prostaglandin F3-Alpha in Bovine Lung: Prostaglandins And Related Factors 26. Biochem Biophys Acta. 1964; 84: 707-713.
9. Said SI, Yoshida T, Kitamura S, Vreim C. Pulmonary alveolar hypoxia: release of prostaglandins and other humoral mediators. Science. 1974; 185(4157): 1181-1183.
10. Singh I, Chohan IS. Adverse changes in fibrinolysis, blood coagulation and platelet function in high altitude pulmonary oedema and their role in its pathogenesis. Int J Biometeor. 1974; 18(1): 33-45.